Vicente Redondo, MD
Infectious Disease · Sterling Heights, MINPI 1598865602
Payments from drug & device makers
Across 10 payments — averaging $114.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$411
- AbbVie$125
- Organogenesis Inc.$123
- Smith+Nephew$114
- Shionogi Inc$110
- Nestle Healthcare Nutrition Inc.$103
- plus $162 from 2 others
What the payments were for
- Food & beverage$1,04991%
- Education$999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 3 | $411 |
| AbbVie | 1 | $125 |
| Organogenesis Inc. | 1 | $123 |
| Smith+Nephew | 1 | $114 |
| Shionogi Inc | 1 | $110 |
| Nestle Healthcare Nutrition Inc. | 1 | $103 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $88 |
| Solventum Corporation | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$178
- DALVANCE$125
- Puraply Antimicrobial$123
- PICO 7$114
- RENASYS TOUCH$114
- Fetroja$110
- VOWST$103
How this compares
$1,148 in reported general payments places this provider in the 70th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 85 | $319,264 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $50,390 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $37,638 |
| PrezcobixDarunavir/Cobicistat | 13 | $29,946 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $26,796 |
| ErtapenemErtapenem Sodium | 14 | $5,111 |
| Entecavir | 12 | $3,857 |
| Methenamine Hippurate | 34 | $2,974 |
| Meropenem | 15 | $2,649 |
| Rifampin | 35 | $1,726 |
| Ethambutol Hcl | 36 | $1,551 |
| Azithromycin | 50 | $1,230 |
| Linezolid | 13 | $1,118 |
| Cefadroxil | 14 | $415 |
| CeftriaxoneCeftriaxone Sodium | 21 | $394 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Sterling Heights
- Syed HusainSterling Heights$396K
- Marcus ZervosDetroit$23.5M
- Louis SaravolatzGrosse Pointe Woods$2.6M
- Smitha GudipatiDetroit$1.9M
- Indira BrarDetroit$1.7M
- Mayur RameshDetroit$1.7M
- Matthew SimsRoyal Oak$1.1M
- Daniel KaulAnn Arbor$1M
- Christopher CarpenterRoyal Oak$1M
- George AlangadenDetroit$987K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.